CJC-1295 (without DAC)
Hormonal and Signaling
ABOUT
CJC-1295 without DAC is kept separate from long-acting DAC-containing formulations. A clinical review identifies CJC-1295 among unapproved peptide therapies but provides no formulation-specific primary evidence for this non-DAC record.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Modified GRF (1-29), often sold as "CJC-1295 without DAC", is a tetrasubstituted GHRH(1-29) analogue whose amino-acid substitutions resist enzymatic degradation. It differs from CJC-1295 with DAC in one decisive way: it carries no maleimide group, so it does not bind covalently to serum albumin and does not acquire the multi-day half-life that defines the DAC version.
PHARMACOKINETICS
No published human pharmacokinetic study exists for the non-DAC analogue. All the frequently quoted half-life and IGF-1 figures - 5.8 to 8.1 days, IGF-1 elevated for up to 28 days - come from Teichman's trials of CJC-1295 WITH DAC and do not apply here. Treating the two as interchangeable is the most common error made about this compound.
REVIEW
PUBLISHED PAIR RECORDS
with Ipamorelin
Growth-hormone axis: documented synergistic releaseCJC-1295 (without DAC) acts at the GHRH receptor while Ipamorelin acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. Ipamorelin is the more receptor-selective secretagogue in this group and has comparatively little effect on prolactin, ACTH and cortisol. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with GHRP-2
Growth-hormone axis: documented synergistic releaseCJC-1295 (without DAC) acts at the GHRH receptor while GHRP-2 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. GHRP-2 also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with GHRP-6
Growth-hormone axis: documented synergistic releaseCJC-1295 (without DAC) acts at the GHRH receptor while GHRP-6 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. GHRP-6 also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Hexarelin
Growth-hormone axis: documented synergistic releaseCJC-1295 (without DAC) acts at the GHRH receptor while Hexarelin acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. Hexarelin also raises prolactin, ACTH and cortisol; in a head-to-head human comparison the ACTH/cortisol-releasing activity of GHRP-2 and hexarelin was similar to that of CRH, while prolactin release was lower than that of TRH. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with MK-677
Growth-hormone axis: documented synergistic releaseCJC-1295 (without DAC) acts at the GHRH receptor while MK-677 acts at the ghrelin/GH-secretagogue receptor. In healthy men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically rather than additively, and the combined area-under-curve response exceeded the arithmetic sum of each given alone. Combining these two classes therefore produces a larger GH and downstream IGF-1 response than either alone. MK-677 is an orally active, long-acting ghrelin-receptor agonist, so the combined effect on the GH/IGF-1 axis is sustained rather than pulsatile, and trials of MK-677 report deterioration of glucose tolerance. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with CJC-1295 with DAC
Same receptor class: overlapping GHRH-receptor activityCJC-1295 (without DAC) and CJC-1295 with DAC are both growth-hormone-releasing-hormone receptor agonists, so they act on the same pituitary receptor population rather than on complementary pathways. Published human work characterises GHRH-receptor and ghrelin-receptor stimulation as the two distinct routes to GH release; two agents from the same route do not provide that documented synergy, and their effects on the GH/IGF-1 axis overlap. Duration differs across this class - DAC-modified and depot-style analogues sustain exposure far longer than short-acting ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Sermorelin
Same receptor class: overlapping GHRH-receptor activityCJC-1295 (without DAC) and Sermorelin are both growth-hormone-releasing-hormone receptor agonists, so they act on the same pituitary receptor population rather than on complementary pathways. Published human work characterises GHRH-receptor and ghrelin-receptor stimulation as the two distinct routes to GH release; two agents from the same route do not provide that documented synergy, and their effects on the GH/IGF-1 axis overlap. Duration differs across this class - DAC-modified and depot-style analogues sustain exposure far longer than short-acting ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Tesamorelin
Same receptor class: overlapping GHRH-receptor activityCJC-1295 (without DAC) and Tesamorelin are both growth-hormone-releasing-hormone receptor agonists, so they act on the same pituitary receptor population rather than on complementary pathways. Published human work characterises GHRH-receptor and ghrelin-receptor stimulation as the two distinct routes to GH release; two agents from the same route do not provide that documented synergy, and their effects on the GH/IGF-1 axis overlap. Duration differs across this class - DAC-modified and depot-style analogues sustain exposure far longer than short-acting ones. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with IGF-1 LR3
Additive IGF-1 receptor signallingCJC-1295 (without DAC) raises IGF-1 indirectly by stimulating growth-hormone release, while IGF-1 LR3 is an IGF-1 analogue that acts directly at the IGF-1 receptor. The two therefore converge on the same downstream signalling. Regulatory labelling for recombinant IGF-1 records that the IGF-1 receptor is homologous to the insulin receptor, that IGF-1 has insulin-like hypoglycaemic effects, and that hypoglycaemia is among its most common adverse effects; doses of insulin or other hypoglycaemic products may need reducing. Growth hormone itself moves blood glucose in the opposite direction, so the net glycaemic effect of the pair is not predictable from either agent alone. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with IGF-1 DES
Additive IGF-1 receptor signallingCJC-1295 (without DAC) raises IGF-1 indirectly by stimulating growth-hormone release, while IGF-1 DES is an IGF-1 analogue that acts directly at the IGF-1 receptor. The two therefore converge on the same downstream signalling. Regulatory labelling for recombinant IGF-1 records that the IGF-1 receptor is homologous to the insulin receptor, that IGF-1 has insulin-like hypoglycaemic effects, and that hypoglycaemia is among its most common adverse effects; doses of insulin or other hypoglycaemic products may need reducing. Growth hormone itself moves blood glucose in the opposite direction, so the net glycaemic effect of the pair is not predictable from either agent alone. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with follistatin-344
Converging on muscle growth from two different directionsFollistatin-344 antagonises myostatin and activin A, removing a brake on skeletal-muscle growth through the SMAD2/3 pathway. CJC-1295 (without DAC) pushes the accelerator instead, raising growth-hormone exposure and downstream IGF-1. These are genuinely distinct pathways converging on the same tissue outcome, which is why the combination is attractive in principle and why its size cannot be predicted from either alone. The evidence does not support treating it as characterised: human follistatin data comes from AAV-delivered gene therapy in open-label muscular-dystrophy trials of a handful of patients, not from injected follistatin protein, and a case series reported central serous chorioretinopathy in bodybuilders using subcutaneous FS-344. Growth factors affecting muscle regeneration are prohibited at all times in sport. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with AOD-9604
Growth-hormone fragment that does not act through the growth-hormone receptorAOD-9604 is the C-terminal fragment of human growth hormone (residues 177-191), and it is commonly scheduled alongside growth-hormone secretagogues on the assumption that it adds to the same axis. It does not: the fragment was designed to reproduce the lipolytic action of growth hormone without its diabetogenic effects, and published work shows its lipolytic action is not mediated directly through the growth hormone receptor. CJC-1295 (without DAC) raises endogenous growth hormone and downstream IGF-1; AOD-9604 does not add to that signal. The more relevant fact is efficacy: FDA's review describes a 502-person obesity trial in which AOD-9604 showed no significant difference from placebo on its primary endpoint, and development did not proceed to approval. AOD-9604 is prohibited by the World Anti-Doping Agency. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 / Ipamorelin blend
Same substance taken twice: blend already contains this compoundCJC-1295 / Ipamorelin blend already contains CJC-1295 (without DAC) at 5 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / GHRP-2 blend
Same substance taken twice: blend already contains this compoundCJC-1295 / GHRP-2 blend already contains CJC-1295 (without DAC). Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / GHRP-6 blend
Same substance taken twice: blend already contains this compoundCJC-1295 / GHRP-6 blend already contains CJC-1295 (without DAC). Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / Hexarelin blend
Same substance taken twice: blend already contains this compoundCJC-1295 / Hexarelin blend already contains CJC-1295 (without DAC). Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains Ipamorelin and CJC-1295 with DAC, and the catalogue holds a curated pair record between those components and CJC-1295 (without DAC): Ipamorelin (growth-hormone axis: documented synergistic release); CJC-1295 with DAC (same receptor class: overlapping ghrh-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Ipamorelin and Sermorelin, and the catalogue holds a curated pair record between those components and CJC-1295 (without DAC): Ipamorelin (growth-hormone axis: documented synergistic release); Sermorelin (same receptor class: overlapping ghrh-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
No clinical trial of the non-DAC analogue has been published. Its use rests on extrapolation from GHRH pharmacology and from the DAC-modified analogue, neither of which establishes what this molecule does in people at the doses used.
REPORTED EFFECTS
No human safety data specific to this analogue exists. Growth-hormone-releasing factors and their analogues are prohibited at all times in sport. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.
RESEARCH LIMITATIONS
The source does not establish the identity, pharmacokinetics, clinical benefit, or safety of a no-DAC formulation. Do not transfer findings or half-life estimates from DAC-containing CJC-1295.
CURATED SOURCES · 3